Brief: Health Canada Issues Resverlogix Authorization To Begin Immediate Clinical Studies Of Apabetalone For Covid-19
12/04/2021 13:10
April 12 (Reuters) - Resverlogix Corp RVX.TO :
* HEALTH CANADA ISSUES RESVERLOGIX AUTHORIZATION TO BEGIN
IMMEDIATE CLINICAL STUDIES OF APABETALONE FOR COVID-19
* RESVERLOGIX CORP - SUCCESSFULLY RECEIVED ITS DESIRED "NO
OBJECTION LETTER" FROM HEALTH CANADA
Source text for Eikon: ID:nGNXygYbq
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment